This company listing is no longer active
Biodexa Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Biodexa Pharmaceuticals has a total shareholder equity of £3.2M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £5.5M and £2.4M respectively.
Key information
0%
Debt to equity ratio
UK£0
Debt
| Interest coverage ratio | n/a |
| Cash | UK£2.84m |
| Equity | UK£3.16m |
| Total liabilities | UK£2.36m |
| Total assets | UK£5.53m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 5MPA's short term assets (£4.7M) exceed its short term liabilities (£1.9M).
Long Term Liabilities: 5MPA's short term assets (£4.7M) exceed its long term liabilities (£463.0K).
Debt to Equity History and Analysis
Debt Level: 5MPA is debt free.
Reducing Debt: 5MPA has no debt compared to 5 years ago when its debt to equity ratio was 18.7%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 5MPA has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 5MPA is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.